AR088919A2 - Derivados de pirazol, composiciones que contienen dichos compuestos y uso - Google Patents
Derivados de pirazol, composiciones que contienen dichos compuestos y usoInfo
- Publication number
- AR088919A2 AR088919A2 ARP120104354A ARP120104354A AR088919A2 AR 088919 A2 AR088919 A2 AR 088919A2 AR P120104354 A ARP120104354 A AR P120104354A AR P120104354 A ARP120104354 A AR P120104354A AR 088919 A2 AR088919 A2 AR 088919A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- groups
- co2r4
- optionally substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos son útiles para tratar la diabetes de tipo 2 y dolencias relacionadas. También se incluyen composiciones farmacéuticas y procedimientos de tratamiento. Reivindicación 1: Un compuesto caracterizado porque está representado por la fórmula (1) o una sal farmacéuticamente aceptables del mismo, en el que: cada R¹ es H o se selecciona del grupo constituido por: (a) halo, OH, CO₂R⁴, CN, SOₚR⁵ o NO₂, (b) alquilo C₁₋₆ o O-alquilo C₁₋₆ opcionalmente sustituido con (I) 1 - 5 grupos halo hasta un grupo perhaloalquilo; (II) CO₂R⁴; (III) fenilo opcionalmente sustituido como sigue: (i) 1 - 5 grupos halo, (ii) 1 grupo CO₂R⁴, CN, S(O)ₚR⁵, NO₂ o C(O)NR⁶R⁷, (iii) 1 - 2 grupos alquilo o alcoxi C₁₋₁₀, cada uno opcionalmente sustituido con: 1 - 5 halo hasta perhaloalquilo, y 1 - 2 grupos OH o CO₂R⁴; cada R² se selecciona de R¹ como se define anteriormente, o se pueden tomar juntos 2 grupos R² para representar una estructura cíclica de 5 - 6 miembros condensada que contiene 1 - 2 átomos de oxígeno, y 1 - 2 átomos de carbono cada uno de los cuales está opcionalmente sustituido con 1 - 2 átomos de F; R³ es H o alquilo C₁₋₃; R⁴ es H, alquilo C₁₋₆, y R⁵ representa un miembro seleccionado del grupo constituido por: alquilo C₁₋₁₀, arilo o alquilo Ar-C₁₋₁₀; R⁶ y R⁷ representan cada uno independientemente H o alquilo C₁₋₃, y p es 0, 1 ó 2; y arilo y Ar se refieren a anillos aromáticos mono o bicíclicos que contienen de 6 - 12 átomos de carbono.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57711604P | 2004-06-04 | 2004-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088919A2 true AR088919A2 (es) | 2014-07-16 |
Family
ID=35335786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102266A AR049291A1 (es) | 2004-06-04 | 2005-06-02 | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| ARP120104354A AR088919A2 (es) | 2004-06-04 | 2012-11-20 | Derivados de pirazol, composiciones que contienen dichos compuestos y uso |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102266A AR049291A1 (es) | 2004-06-04 | 2005-06-02 | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7598285B2 (es) |
| EP (1) | EP1756064B1 (es) |
| JP (2) | JP4108739B2 (es) |
| CN (1) | CN1964947A (es) |
| AR (2) | AR049291A1 (es) |
| AT (1) | ATE395338T1 (es) |
| AU (2) | AU2005252183B2 (es) |
| BR (1) | BRPI0511703B8 (es) |
| CA (1) | CA2566945C (es) |
| CR (1) | CR8766A (es) |
| CY (1) | CY1108544T1 (es) |
| DE (1) | DE602005006806D1 (es) |
| DK (1) | DK1756064T3 (es) |
| EA (1) | EA012431B1 (es) |
| EC (1) | ECSP067062A (es) |
| ES (1) | ES2306165T3 (es) |
| GE (1) | GEP20094605B (es) |
| HR (1) | HRP20080311T3 (es) |
| IL (1) | IL179754A (es) |
| MA (1) | MA28673B1 (es) |
| MX (1) | MXPA06014084A (es) |
| MY (1) | MY143599A (es) |
| NI (1) | NI200600290A (es) |
| NO (1) | NO339149B1 (es) |
| NZ (1) | NZ551405A (es) |
| PE (1) | PE20060427A1 (es) |
| PL (1) | PL1756064T3 (es) |
| PT (1) | PT1756064E (es) |
| SI (1) | SI1756064T1 (es) |
| TN (1) | TNSN06397A1 (es) |
| TW (1) | TWI293952B (es) |
| UA (1) | UA85884C2 (es) |
| WO (1) | WO2005121097A2 (es) |
| ZA (1) | ZA200609489B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1590336B1 (en) | 2003-01-27 | 2010-12-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP4108739B2 (ja) | 2004-06-04 | 2008-06-25 | メルク エンド カムパニー インコーポレーテッド | ピラゾール誘導体、かかる化合物を含む組成物及び使用方法 |
| JP2008507528A (ja) * | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
| EP1910303A2 (en) * | 2005-07-26 | 2008-04-16 | Merck & Co., Inc. | Process for synthesizing a substituted pyrazole |
| AR056574A1 (es) * | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| WO2008087029A1 (en) * | 2007-01-17 | 2008-07-24 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds with acat inhibition activity |
| ES2720430T3 (es) | 2007-02-09 | 2019-07-22 | Metabasis Therapeutics Inc | Antagonistas novedosos del receptor de glucagón |
| WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| WO2009035558A1 (en) * | 2007-09-12 | 2009-03-19 | Merck & Co., Inc. | Process for the production of a crystalline glucagon receptor antagonist compound |
| EP2251326A4 (en) * | 2008-03-05 | 2011-08-31 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| AU2009224418B2 (en) | 2008-03-11 | 2014-12-11 | Aska Pharmaceutical Co., Ltd. | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both |
| AU2009246424A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
| ES2527670T3 (es) | 2008-08-13 | 2015-01-28 | Metabasis Therapeutics, Inc. | Antagonistas de glucagón |
| RU2008135294A (ru) * | 2008-08-29 | 2010-03-10 | Дик Корпорейшн (Jp) | Нафталиновые производные |
| US8436015B2 (en) * | 2008-09-15 | 2013-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| AR073412A1 (es) * | 2008-10-03 | 2010-11-03 | Schering Corp | Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende. |
| WO2010093535A1 (en) | 2009-02-12 | 2010-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| EP2440553B1 (en) * | 2009-06-12 | 2017-08-23 | Merck Sharp & Dohme Corp. | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| EP2480077B1 (en) | 2009-09-22 | 2015-02-18 | Merck Sharp & Dohme Corp. | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use |
| AU2011346670B2 (en) | 2010-12-23 | 2015-05-07 | Pfizer Inc. | Glucagon receptor modulators |
| ME02502B (me) | 2011-02-08 | 2017-02-20 | Pfizer | Modulator glukagonskog receptora |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| WO2015066252A1 (en) | 2013-11-04 | 2015-05-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
| CN103933032B (zh) * | 2013-12-30 | 2019-08-23 | 北京赛林泰医药技术有限公司 | 作为抗癌药物的吡唑类衍生物的使用方法和用途 |
| WO2015191900A1 (en) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
| EP3506940A1 (en) | 2016-08-30 | 2019-07-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| TWI763705B (zh) * | 2016-09-06 | 2022-05-11 | 比利時商健生藥品公司 | 可作為升糖素受體拮抗劑之吲哚衍生物 |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| EP3672620A1 (en) | 2017-08-22 | 2020-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling |
| EP3752249A1 (en) | 2018-02-13 | 2020-12-23 | Ligand Pharmaceuticals, Inc. | Glucagon receptor antagonists |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9303993D0 (en) * | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
| AU702887B2 (en) | 1995-10-31 | 1999-03-11 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| AU730295B2 (en) | 1996-11-20 | 2001-03-01 | Merck & Co., Inc. | Triaryl substituted imidazoles as glucagon antagonists |
| WO1998022108A1 (en) | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles and methods of use |
| EP0948257A4 (en) | 1996-11-20 | 1999-12-29 | Merck & Co Inc | TRIARYL-SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME AND METHOD FOR THEIR USE |
| AU5410498A (en) * | 1996-12-12 | 1998-07-03 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| EA199900837A1 (ru) | 1997-04-18 | 2000-10-30 | Дж.Д.Сирл Энд Ко. | Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| DK1042293T3 (da) | 1997-12-19 | 2008-07-14 | Amgen Inc | Substituerede pyridin- og pyridazinforbindelser og deres farmaceutiske anvendelse |
| BR9913833A (pt) | 1998-09-17 | 2001-05-29 | Bristol Myers Squibb Co | Método para tratar diabetes, empregando em inibidor de ap2 e combinação |
| US6503949B1 (en) * | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| KR100730019B1 (ko) * | 1999-08-10 | 2007-06-20 | 바이엘 크롭사이언스 케이. 케이. | 제초성 테트라졸리논 유도체 |
| PT1228067E (pt) * | 1999-11-10 | 2004-11-30 | Takeda Chemical Industries Ltd | Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica |
| US6562807B2 (en) * | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| DE60128475T2 (de) * | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
| WO2002040444A1 (en) | 2000-11-17 | 2002-05-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| ITMI20010733A1 (it) * | 2001-04-05 | 2002-10-05 | Recordati Chem Pharm | Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria |
| US6762318B2 (en) * | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| AU2002351730A1 (en) | 2001-12-19 | 2003-06-30 | Novo Nordisk A/S | Glucagon receptor antagonists/inverse agonists |
| AU2002347022A1 (en) | 2001-12-20 | 2003-07-09 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
| MXPA04007474A (es) * | 2002-02-01 | 2004-11-10 | Dainippon Pharmaceutical Co | Hidrazidas del acido 2-furancarboxilico y composiciones farmaceuticas que la contienen. |
| DE60336724D1 (de) | 2002-07-19 | 2011-05-26 | Baxter Healthcare Sa | System für die peritonealdialyse |
| EP1400243A1 (en) | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
| AU2003298889A1 (en) * | 2002-12-04 | 2004-06-23 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
| EP1590336B1 (en) * | 2003-01-27 | 2010-12-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| EA200501607A1 (ru) * | 2003-04-14 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые фенилалкановые кислоты |
| EP1626717A4 (en) * | 2003-05-09 | 2009-09-09 | Merck & Co Inc | BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS |
| JP4108739B2 (ja) | 2004-06-04 | 2008-06-25 | メルク エンド カムパニー インコーポレーテッド | ピラゾール誘導体、かかる化合物を含む組成物及び使用方法 |
| JP2008507528A (ja) * | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
| AR056574A1 (es) * | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
-
2005
- 2005-05-31 JP JP2007515416A patent/JP4108739B2/ja not_active Expired - Fee Related
- 2005-05-31 MY MYPI20052470A patent/MY143599A/en unknown
- 2005-05-31 GE GEAP20059788A patent/GEP20094605B/en unknown
- 2005-05-31 PL PL05754758T patent/PL1756064T3/pl unknown
- 2005-05-31 NZ NZ551405A patent/NZ551405A/en not_active IP Right Cessation
- 2005-05-31 ES ES05754758T patent/ES2306165T3/es active Active
- 2005-05-31 CA CA2566945A patent/CA2566945C/en not_active Expired - Fee Related
- 2005-05-31 CN CNA2005800182634A patent/CN1964947A/zh active Pending
- 2005-05-31 BR BRPI0511703A patent/BRPI0511703B8/pt not_active IP Right Cessation
- 2005-05-31 DE DE602005006806T patent/DE602005006806D1/de active Active
- 2005-05-31 DK DK05754758T patent/DK1756064T3/da active
- 2005-05-31 UA UAA200700111A patent/UA85884C2/uk unknown
- 2005-05-31 WO PCT/US2005/018828 patent/WO2005121097A2/en active IP Right Grant
- 2005-05-31 EA EA200602196A patent/EA012431B1/ru not_active IP Right Cessation
- 2005-05-31 MX MXPA06014084A patent/MXPA06014084A/es active IP Right Grant
- 2005-05-31 PT PT05754758T patent/PT1756064E/pt unknown
- 2005-05-31 AT AT05754758T patent/ATE395338T1/de active
- 2005-05-31 AU AU2005252183A patent/AU2005252183B2/en not_active Ceased
- 2005-05-31 EP EP05754758A patent/EP1756064B1/en active Active
- 2005-05-31 SI SI200530296T patent/SI1756064T1/sl unknown
- 2005-06-02 AR ARP050102266A patent/AR049291A1/es active IP Right Grant
- 2005-06-02 PE PE2005000624A patent/PE20060427A1/es not_active Application Discontinuation
- 2005-06-03 US US11/144,332 patent/US7598285B2/en active Active
- 2005-06-03 TW TW094118496A patent/TWI293952B/zh not_active IP Right Cessation
-
2006
- 2006-11-15 ZA ZA200609489A patent/ZA200609489B/en unknown
- 2006-11-23 CR CR8766A patent/CR8766A/es unknown
- 2006-11-30 NI NI200600290A patent/NI200600290A/es unknown
- 2006-11-30 IL IL179754A patent/IL179754A/en active IP Right Grant
- 2006-12-01 TN TNP2006000397A patent/TNSN06397A1/en unknown
- 2006-12-04 EC EC2006007062A patent/ECSP067062A/es unknown
- 2006-12-20 MA MA29545A patent/MA28673B1/fr unknown
-
2007
- 2007-01-04 NO NO20070073A patent/NO339149B1/no not_active IP Right Cessation
-
2008
- 2008-02-05 JP JP2008025035A patent/JP4733153B2/ja not_active Expired - Fee Related
- 2008-07-01 HR HR20080311T patent/HRP20080311T3/xx unknown
- 2008-07-21 CY CY20081100762T patent/CY1108544T1/el unknown
- 2008-09-30 AU AU2008229701A patent/AU2008229701C1/en not_active Ceased
-
2009
- 2009-03-17 US US12/405,600 patent/US7799818B2/en active Active
-
2012
- 2012-11-20 AR ARP120104354A patent/AR088919A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR106755A2 (es) | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| PA8609201A1 (es) | Piridinonas sustituidas | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CR8756A (es) | Derivados de acido carboxilico bencimidazolona | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| UY29869A1 (es) | Compuestos de benzamida | |
| ECSP11010901A (es) | Compuestos de amida útiles en terapia | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| AR090376A1 (es) | Compuestos herbicidas | |
| AR067927A1 (es) | Quinolinas sustituidas, composiciones y combinaciones que las comprenden y el uso de las mismas en la preparacion de un medicamento para tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio. | |
| DE502006004182D1 (de) | Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2-aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| AR048573A1 (es) | Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima | |
| CL2011000551A1 (es) | Sal difosfato de n-[6-(cis-2,6-dimetil morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro metoxi)-[1,1'-bifenil]-3-carboxamida; composicion farmaceutica,y su uso para tratar enfermedades que respondan a la modulacion de la actividad de la senda de señalizacion de hedgehog, tales como carcinoma y leucemia. | |
| PE20240886A1 (es) | Compuestos espirociclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |